Table III.
Variable | Patient number | Univariate analysis
|
Multivariate analysis
|
||
---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | ||
Tumor size (cm) | 159 | 0.600 | |||
≤5 | 1 | 1 | |||
>5 | 2.078 (1.467–2.942) | 0.000 | 1.348 (0.607–2.995) | ||
Tumor nodules | 159 | 0.092 | |||
Solitary | 1 | 1 | |||
Multiple | 2.371 (1.542–3.647) | 0.000 | 1.206 (0.836–3.641) | ||
Capsular formation | 154 | 0.104 | |||
Absence | 1 | ||||
Presence | 0.753 (0.532–1.065) | 0.109 | 0.732 (0.503–1.066) | ||
Microscopic vascular invasion | 157 | 0.003 | |||
Absence | 1 | 1 | |||
Presence | 2.737 (1.900–3.943) | 0.000 | 2.033 (1.357–3.046) | ||
Serum α-fetoprotein level (ng/ml) | 149 | 0.090 | |||
≤400 | 1 | 1 | |||
>400 | 1.495 (1.037–2.154) | 0.031 | 1.306 (0.893–1.909) | ||
Edmondson-steiner grade | 158 | 0.527 | |||
1,2 | 1 | 1 | |||
3,4 | 1.027 (0.969–1.089) | 0.374 | 1.024 (0.952–1.101) | ||
BCLC stage | 159 | 0.451 | |||
A | 1 | 1 | |||
B | 2.355 (1.654–3.354) | 0.000 | 1.329 (0.581–3.040) | ||
MBD2 expression | 159 | 0.022 | |||
Negative | 1 | 1 | |||
Positive | 2.128 (1.485–3.049) | 0.000 | 1.513 (1.018–2.248) |
OS, overall survival; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; MBD2, methyl-CpG binding domain 2.